Syndulko K, Gilden E R, Hansch E C, Potvin A R, Tourtellotte W W, Potvin J H
Int J Neurosci. 1981;14(1-2):61-6. doi: 10.3109/00207458108985816.
The effects of chronic administration of the anticholinergic agent, benztropine mesylate (CogentinTM), on specific verbal memory were investigated as part of a placebo-controlled randomized double-blind crossover study to determine the clinical efficiency of CogentinTM as an adjuvant therapy with SinemetTM in Parkinson's disease. Twenty-nine males with clinically definite idiopathic Parkinson's disease participated in the trial. They were tested for acquisition of new word lists, and on four other cognitive tests before, during, between, and after two 10-week trial periods when they received either increasing doses of CogentinTM (maximum 2 mg) or placebo while on a maintenance dose of SinemetTM. Patients showed a statistically significant decrease (5--10%) in word list acquisition while on CogentinTM. The anticholinergic memory effect was unrelated to the degree of improved clinical efficacy of CogentinTM for the Parkinsonism, and to initial word list acquisition ability. Verbal memory findings indicate that chronic administration of an anticholinergic in even low therapeutic dosage may play an important role in memory function.
作为一项安慰剂对照的随机双盲交叉研究的一部分，研究了抗胆碱能药物甲磺酸苯扎托品（安坦）长期给药对特定言语记忆的影响，以确定安坦作为左旋多巴/卡比多巴复合制剂（息宁）辅助治疗帕金森病的临床疗效。29名临床确诊的特发性帕金森病男性患者参与了该试验。在两个为期10周的试验期内，他们在接受递增剂量的安坦（最大剂量2毫克）或安慰剂的同时服用维持剂量的息宁，在此期间及前后，对他们进行了新单词列表学习测试以及其他四项认知测试。服用安坦期间，患者的单词列表学习能力出现了统计学上的显著下降（5%-10%）。抗胆碱能药物对记忆的影响与安坦对帕金森病临床疗效的改善程度以及初始单词列表学习能力无关。言语记忆研究结果表明，即使是低治疗剂量的抗胆碱能药物长期给药也可能在记忆功能中起重要作用。
